导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 27.45% | 182/4773 |
| 近一周 | 1.83% | 501/5467 |
| 近一月 | -11.02% | 4922/5421 |
| 近一季 | -16.03% | 4271/5238 |
| 近半年 | 24.40% | 180/4931 |
| 近一年 | 29.71% | 213/4400 |
| 近两年 | 175.39% | 135/2954 |
| 近三年 | 119.26% | 92/2253 |
| 成立以来 | 54.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.41% 4131/4961 |
101.25% 97/5312 |
- - |
- - |
| 2025 | 38.52% 866/4813 |
0.45% 1844/3635 |
-0.37% 2906/4076 |
50.35% 312/4524 |
-7.95% 3853/4813 |
| 2024 | 28.15% 164/3463 |
-9.05% 2262/2808 |
0.40% 620/3014 |
17.55% 1166/3129 |
19.38% 54/3463 |
| 2023 | -6.36% 836/2656 |
13.70% 261/2280 |
-7.95% 1938/2385 |
-9.49% 1835/2515 |
-1.15% 295/2655 |
| 2022 | -37.47% 1756/2207 |
-21.12% 1603/1919 |
0.68% 1533/2016 |
-20.76% 1875/2113 |
-0.64% 1635/2208 |
| 2021 | 31.51% 64/1822 |
-7.96% 1071/1255 |
39.17% 21/1330 |
-3.11% 614/1466 |
5.95% 251/1822 |
| 2020 | - - |
- - |
- - |
-3.92% 1100/1164 |
6.62% 752/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏国证半导体芯片ETF联接C VS. 长安沪深300非周期A(740101) |